Alcon posts 256-patient data while Alcon stock sits 21.38 percent below its high

Published on 10/12/2026 at 10:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Systane data met non-inferiority on October 2, 2026. Alcon stock costs EUR 57.27 on October 12, 2026 versus EUR 72.84.

Key points in brief

Alcon reported October 2, 2026 clinical data from a 256-patient study of Systane PRO Preservative-Free.
Systane PRO Preservative-Free delivered comparable dry eye relief to the comparator at two weeks and one month.
Alcon stock was trading at EUR 57.27 at Lang & Schwarz on October 12, 2026, while the cited EUR 72.84 52-week high was 21.38 percent higher.
Alcon's next reported quarterly results were scheduled for November 10, 2026.

Architectural photography of a modern medical technology corporate headquarters. Glass curtain wall facade with geometric steel grid, elevated skywalks connecting two wings, landscaped plaza with reflecting pool, cool blue-grey tonality — Alcon CH0432492467: Modernes Med Tech Hauptquartier mit Glasfassade, verbindenden Skywalks und einem Spiegelbecken, Illustration mit AI erstellt.

Alcon (ISIN CH0432492467) reported clinical data on October 2, 2026, from a 256-patient study showing that Systane PRO Preservative-Free met its non-inferiority endpoint against the comparator at two weeks and one month, according to Alcon. Alcon stock was trading at EUR 57.27 at Lang & Schwarz on October 12, 2026 at 10:04 a.m. CEST.

Clinical evidence adds product depth

The study compared Systane PRO Preservative-Free with perfluorohexyloctane four times daily and assessed symptoms at two weeks and one month. The company said both treatment groups achieved statistically significant reductions in Ocular Surface Disease Index symptoms, with p values of 0.004 at two weeks and 0.01 at one month, according to Alcon.

The product was also launched in Canada in late September. Joplin Globe reported that the preservative-free formula was available in Canada from September 28, 2026, with relief of dry eye symptoms for up to 12 hours.

What comes next for Alcon?

Alcon's operating calendar includes two dated milestones. The contract manufacturing agreement with Lifecore Biomedical is scheduled to take effect on November 1, 2026, and the next quarterly results were scheduled for November 10, 2026, according to Boerse Express and Stock World.

The product evidence gives investors a measurable commercial and clinical marker before the results date. Alcon's investor-relations page identifies the second-quarter 2026 report as its latest quarterly reporting package, while the company says its Surgical and Vision Care products reach more than 260 million people in over 140 countries each year, according to Alcon.

Stock remains below its yearly high

The EUR 57.27 Lang & Schwarz quote is 21.38 percent below the EUR 72.84 52-week high cited for October 9, 2026. The same dated market reference placed the 52-week low at EUR 52.68, leaving the current euro quote EUR 4.59 above that low.

The stock's primary listing is on SIX under ticker ALC.SW, and Alcon is included in the SMI, according to Global Banking & Finance Review. The further course of trading is shown by the continuously updated real-time quote of Alcon stock.